TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18394022
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (Simvastatin and Simvastatin/Ezetimibe)
Study: 9239452
Drug: Miglitol administered
Normalized name: Miglitol
DrugBank: Miglitol (DB00491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Miglitol administered via intravenous route
Study: 9239452
Drug: Miglitol administered
Normalized name: Miglitol
DrugBank: Miglitol (DB00491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Miglitol administered via oral route
Study: 9239452
Drug: Repeated administration
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated administration of miglitol to rats
Study: 8452648
Drug: Combination pyrimethamine-sulfadiazine
Normalized name: pyrimethamine / sulfadiazine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination pyrimethamine-sulfadiazine and spiramycine
Study: 3777901
Drug: Low-dose ticarcillin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ticarcillin (50 mg/kg)
Study: 3777901
Drug: High-dose ticarcillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ticarcillin (80 mg/kg)
Study: 30327982
Drug: Intramuscular group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular group (IM)
Study: 26910660
Drug: Perlane-L
Normalized name: Perlane
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perlane-L
Study: 24927436
Drug: Probiotics administered
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics administered from the day enteral feeding began
Study: 22956296
Drug: Healthy lifestyles
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy lifestyles intervention (Year 1: targeted home visits; Year 2: monthly newsletters and group meetings)
Study: 22956296
Drug: Control (curricula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (curricula materials during Year 1; monthly newsletters during Year 2)
Study: 16319040
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium (2 g IV Mg)
Study: 8895675
Drug: Isolated liver
Normalized name: LIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isolated liver perfusion with 30 mg/m2 mitomycin C (MMC) recirculated for one hour
Study: 8895675
Drug: Isolated liver
Normalized name: LIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isolated liver perfusion with 30 mg/m2 mitomycin C (MMC)
Study: 1992381
Drug: Flunarizine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunarizine (10 mg/d)
Study: 6220895
Drug: Nifedipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (20 mg acute; 20 mg q.i.d. for 1 month)
Study: 6220895
Drug: Verapamil (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (160 mg acute; 160 mg t.i.d. for 1 month)
Study: 30824336
Drug: DMET (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMET (1 mg/kg delivered over 10 minutes at the time of surgical closure)
Study: 20694277
Drug: Enoxaparin (prophylactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (prophylactic daily dose starting from positive pregnancy test)
Study: 9003961
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (transcranial electrostimulation)
Study: 6735252
Drug: Indomethacin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (75 mg sustained release capsules taken 12 and 24 hours before, and 50 mg taken one hour before histamine infusion)
Study: 6735252
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsules
Study: 25387282
Drug: Lopinavir/ritonavir monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir/ritonavir monotherapy (LPV/r-MT) 400/100 mg BID
Study: 25387282
Drug: Lopinavir/ritonavir monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir/ritonavir monotherapy (LPV/r-MT)
Study: 12500989
Drug: Bovine colostrum
Normalized name: Bovine Colostrum
DrugBank: Bos taurus colostrum (DB19249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bovine colostrum (60 g daily)
Study: 25833983
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein (60 g daily)
Study: 11966624
Drug: Mitomycin-C (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitomycin-C (40 mg)
Study: 11966624
Drug: Interferon-alpha (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-alpha (all doses)
Study: 9661606
Drug: Nal‐Glu GnRH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nal‐Glu GnRH antagonist (5, 15, 50, and 150 micrograms/kg)
Study: 9661606
Drug: Nal‐Glu GnRH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nal‐Glu GnRH antagonist (150 micrograms/kg for 3-7 days)
Study: 29554849
Drug: Dose-equivalent usual
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-equivalent usual occupational therapy (DEUCC)
Study: 29554849
Drug: Usual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual therapy (UCC)
Study: 20528593
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone propionate (FP; 400 microg/day)
Study: 15786853
Drug: Exposed enrollees
Normalized name: lactose, x-ray exposed (1000 rad)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposed enrollees taking potentially contraindicated medications
Study: 15786853
Drug: Unexposed enrollees
Normalized name: lactose, x-ray exposed (1000 rad)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unexposed enrollees not taking potentially contraindicated medications
Study: 14614228
Drug: Flutamide treatment
Normalized name: Flutamide
DrugBank: Flutamide (DB00499)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flutamide treatment for 4 weeks
Study: 1987737
Drug: Epirubicin (Epi)
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epirubicin (Epi) 20 mg/m2 i.v. weekly
Study: 1987737
Drug: Doxorubicin (Dox)
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin (Dox) 20 mg/m2 i.v. weekly
Study: 6307941
Drug: Prophylactic chemotherapy
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic chemotherapy (cyclophosphamide and CCNU)
Study: 6307941
Drug: Delayed chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed chemotherapy (cyclophosphamide and CCNU)
Study: 6307941
Drug: Thoracic irradiation
Normalized name: Thoracol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracic irradiation (TI), brain irradiation (BI), and early chemotherapy (CT)
Study: 6307941
Drug: Thoracic irradiation
Normalized name: Thoracol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracic irradiation (TI) and chemotherapy (CT)
Study: 29504254
Drug: Oral cholecalciferol
Normalized name: cholecalciferol Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cholecalciferol at 25,000 IU/wk
Study: 27176725
Drug: Hydrogen water
Normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrogen water (1000 mL/day)
Study: 12271348
Drug: Prompt L‐Pop
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prompt L‐Pop (LP)
Study: 9163011
Drug: Cisplatin administered
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin administered in the evening (Group A)
Study: 9163011
Drug: Cisplatin administered
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin administered in the morning (Group B)
Study: 1937374
Drug: 2 x
Normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x 400 mg cimetidine daily for 10 days
Study: 1937374
Drug: 2 x
Normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x 400 mg cimetidine daily for 28 days
Study: 7023678
Drug: Placebo (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (one tablet after lunch and one at bedtime)
Study: 27355267
Drug: Insulin (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin (standard of care)
Study: 18535027
Drug: Individualised rehabilitation
Normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualised rehabilitation programme (treatment group, n = 49)
Study: 15992459
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (4 mg every 3 weeks)
Study: 10731304
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium (4 mg) given 30 min or 3.5 hours before exertion
Study: 10731304
Drug: Chronic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic treatment with Nedocromil sodium for 2 and 4 weeks
Study: 7594444
Drug: Sinorphan (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sinorphan (100 mg twice a day)
Study: 7594444
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy of Sinorphan and Captopril
Study: 7594444
Drug: Sinorphan alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sinorphan alone or in combination with Captopril
Study: 7272867
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy only (Control)
Study: 23453391
Drug: Ergocalciferol 50,000
Normalized name: ergocalciferol 50,000 intl units oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ergocalciferol 50,000 IU once weekly for 12 weeks
Study: 21425568
Drug: Composite Sophora
Normalized name: Sophora pachycarpa whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Composite Sophora Colon‐soluble Capsules (CSCC) plus Etiasa simulated placebo for 8 weeks
Study: 11730742
Drug: Crinone 8%
Normalized name: Crinone 8% Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crinone 8% (90 mg once daily)
Study: 10560985
Drug: IM progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IM progesterone (50 mg once daily)
Study: 9164992
Drug: Acarbose (50-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose (50-200 mg, three times per day)
Study: 8083699
Drug: Quinidine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinidine (250 mg) capsules taken for 4 days before and 2 days after chemotherapy
Study: 2769131
Drug: Iodophor cream
Normalized name: iodophors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodophor cream
Study: 2769131
Drug: Chlorhexidine cream
Normalized name: chlorhexidine Topical Cream
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorhexidine cream
Study: 239807
Drug: Lorazepam 1.33
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam 1.33 mg intramuscularly
Study: 239807
Drug: Lorazepam 4
Normalized name: lorazepam 4 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam 4 mg intramuscularly
Study: 1170
Drug: Pentobarbital 50
Normalized name: PENTobarbital 50 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentobarbital 50 mg
Study: 239807
Drug: Pentobarbital 150
Normalized name: Pentobarbital
DrugBank: Pentobarbital (DB00312)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentobarbital 150 mg
Study: 18308009
Drug: Oral testosterone
Normalized name: testosterone Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral testosterone undecanoate (TU; 80 mg twice daily)
Study: 11191009
Drug: Domperamol (fixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperamol (fixed combination of domperidone and paracetamol)
Study: 8772902
Drug: Isoniazid 5
Normalized name: isoniazid 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoniazid 5 mg/kg
Study: 1993561
Drug: Minoxidil gel
Normalized name: Minoxidil
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Minoxidil gel
Study: 30261084
Drug: Omission of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omission of ACEI therapy
Study: 30261084
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of ACEI therapy
Study: 24809233
Drug: Sublingual administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual administration of 3 mg tacrolimus powder for 15 min
Study: 24809233
Drug: Rectal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rectal administration of 15 mg tacrolimus suppository
Study: 24809233
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of 7 mg tacrolimus capsules (Prograf)
Study: 19329465
Drug: Periodontal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periodontal therapy and oral hygiene instruction in the third trimester
Study: 15766369
Drug: No periodontal
Approvals — FDA: no, EMA: no, PMDA: no
Description: No periodontal treatment (Control)
Study: 15177793
Drug: Imitation (concurrent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imitation (concurrent (CI) and delayed (DI))
Study: 11779723
Drug: Montelukast 10
Normalized name: montelukast 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast 10 mg once daily for 4 weeks
Study: 2564782
Drug: Atracurium (0.92‐0.98
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium (0.92‐0.98 mg kg‐1) administered by continuous infusion or intermittent bolus doses
Study: 2564782
Drug: Vecuronium (0.16‐0.18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium (0.16‐0.18 mg kg‐1) administered by continuous infusion or intermittent bolus doses
Study: 2564782
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving no neuromuscular blocking drugs
Study: 606784
Drug: All vaccine
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All vaccine preparations
Study: 26112148
Drug: Heating and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heating and cooling combination therapy (OCH-S100), 10 treatments (15 min each) over 4 weeks, consisting of five cycles of heating/cooling therapy (max: 45 °C, min: 15 °C).
Study: 26112148
Drug: Sham therapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham therapy, 10 treatments (15 min each) over 4 weeks, consisting of five cycles of sham therapy (max: 1 °C above skin temperature, min: 1 °C below skin temperature).
Study: 16408206
Drug: rHEPO+G‐CSF (10,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHEPO+G‐CSF (10,000 IU rHEPO s.c. three times a week + 300 mug G‐CSF s.c. twice a week)
Study: 16408206
Drug: rHEPO+G‐CSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHEPO+G‐CSF
Study: 9250230
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group (n = 141) received antibiotic-related suggestions from an infectious disease fellow and a clinical pharmacist.
Study: 9250230
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (n = 111) did not receive antibiotic-related suggestions.
Study: 12079004
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg nizatidine
Study: 1676392
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg nizatidine
Study: 8099802
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg nizatidine
Study: 1889143
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg pirenzepine
Study: 8099802
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg nizatidine plus 100 mg pirenzepine
Study: 3332556
Drug: Sequential combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential combination with progestagen
Study: 23238504
Drug: Preoperative radiotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative radiotherapy (25 Gy in 5 fractions) and postoperative chemotherapy (5-fluorouracil and leucovorin)
Study: 20564352
Drug: PEG‐IFN‐lambda at
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐IFN‐lambda at 1.5 or 3.0 microg/kg administered every 2 weeks or weekly for 4 weeks (Part 1)
Study: 20564352
Drug: Weekly doses
Normalized name: selinexor
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly doses of PEG‐IFN‐lambda ranging from 0.5 to 2.25 microg/kg in combination with ribavirin (RBV) for 4 weeks (Part 2)
Study: 20564352
Drug: Weekly PEG‐IFN‐lambda
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly PEG‐IFN‐lambda at 1.5 microg/kg in combination with RBV for 4 weeks (Part 3)
Study: 12447009
Drug: 0.125% dextrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125% dextrin sulfate (DS) gel
Study: 550158
Drug: Indomethacin (prostaglandin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (prostaglandin synthesis inhibitor)
Study: 31488213
Drug: Iloprost 1
Normalized name: ILOPROST 100MCG/ML INJ,SOLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iloprost 1 ng/kg/min and eptifibatide 0.5 μg/kg/min for 48 hours
Study: 19736900
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg oxycodone administered intravenously over 2 minutes
Study: 19736900
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg oxycodone administered intravenously over 15 minutes
Study: 19736900
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg oxycodone administered intravenously
Study: 3127965
Drug: Oxamniquine at
Normalized name: oxamniquine
DrugBank: Oxamniquine (DB01096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxamniquine at 20 mg/kg
Study: 3127965
Drug: Oxamniquine at
Normalized name: oxamniquine
DrugBank: Oxamniquine (DB01096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxamniquine at 30 mg/kg
Study: 3127965
Drug: Oxamniquine at
Normalized name: oxamniquine
DrugBank: Oxamniquine (DB01096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxamniquine at 40 mg/kg
Study: 3127965
Drug: Praziquantel at
Normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Praziquantel at 20 mg/kg
Study: 3127965
Drug: Praziquantel at
Normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Praziquantel at 30 mg/kg
Study: 3127965
Drug: Praziquantel at
Normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Praziquantel at 40 mg/kg
Study: 31451351
Drug: Amikacin liposome
Normalized name: AMIKACIN LIPOSOME
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amikacin liposome inhalation suspension (ALIS, 590 mg QD)
Study: 31451351
Drug: Tobramycin inhalation
Normalized name: Tobramycin Inhalation Powder
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tobramycin inhalation solution (TIS, 300 mg BID)
Study: 29145631
Drug: Rifaximin 550
Normalized name: rifAXIMin 550 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifaximin 550 mg twice daily for 3 days
Study: 22879633
Drug: Metformin 850
Normalized name: metFORMIN 850 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 850 mg twice a day
Study: 20470299
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily icodextrin
Study: 20470299
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily icodextrin
Study: 16634988
Drug: Sibutramine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine with cognitive-behavioural weight loss treatment
Study: 16634988
Drug: Cognitive-behavioural weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural weight loss treatment alone
Study: 8815168
Drug: D-ribose (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-ribose (60 g daily for 7 days)
Study: 6436879
Drug: Ultra-low yielding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra-low yielding cigarette (0.1 mg nicotine) for 10 days
Study: 28370266
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate 220 mcg dry powder inhalation
Study: 26978751
Drug: Streptococcus salivarius
Normalized name: Streptococcus salivarius
DrugBank: Streptococcus salivarius (DB19274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Streptococcus salivarius K12‐based probiotic complex during 30 days in combination with nasal douche
Study: 14747210
Drug: cPPG >150
Approvals — FDA: no, EMA: no, PMDA: no
Description: cPPG >150 mg/dl
Study: 10532976
Drug: Hybrid laser
Normalized name: Amaranthus hybridus pollen
DrugBank: Amaranthus hybridus pollen (DB15503)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hybrid laser treatment
Study: 3169116
Drug: Inhaled adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled adenosine at a concentration of 5 mg.ml‐1
Study: 3169116
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of a comparable dose of adenosine
Study: 31253145
Drug: Volar plating
Normalized name: platinic chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volar plating (surgical treatment with open reduction and internal fixation using volar locking plates)
Study: 31253145
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (closed reduction and plaster immobilization)
Study: 28403911
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care with monthly social assistance, domotic, and remote assistance
Study: 21994429
Drug: U-500R insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: U-500R insulin (50 units)
Study: 21994429
Drug: U-500R insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: U-500R insulin (100 units)
Study: 21994429
Drug: U-100R insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: U-100R insulin (50 units)